secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001213900-25-047890
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Nektar shareholders approve authorized share increase to 390M and reverse split authorization
--------------------------------------------------------------------------------

- Proposal 5: authorized common shares increased from 300M to 390M (92.5M for, 55.5M against).
- Proposal 6: Board authorized to effect reverse stock split at ratio 1:2 to 1:40 within one year (140M for).
- Proposal 2: 2017 Performance Incentive Plan amended to add 6M shares (72.4M for, 28.8M against).
- Directors Diana Brainard and R. Scott Greer elected; other directors continue.
- Ernst & Young ratified as auditor; say-on-pay advisory resolution passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/0001213900-25-047890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/ea0243394-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-047890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer